An Exploratory Phase II Study of PHA-739358 in Patients with Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression

erviano Medical Sciences S.r.l.0 个研究点目标入组 20 人开始时间: 2008年2月28日最近更新: 2022年4月4日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 20

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Adult (age = 18 and = 75 years) patients.
•2. Confirmed diagnosis of active multiple myeloma that has relapsed or is refractory to at least two previous lines of treatments, including bortezomib and lenalidomide. At least 4 weeks should be elapsed between the end of the last therapy and the entry in the trial.
•3. Patients with t (4;14) translocation.
•4. Current measurable disease defined by at least one of the following two measurements:
•· Serum M-protein = 1 g/dl
•· Urine M-protein = 200 mg/24 h.
•5. Prior radiotherapy is allowed provided that no more than 25% of bone marrow reserve has been irradiated and a minimum of 4 weeks have elapsed between the end of prior radiotherapy and the entry into the trial or less if one single lesion had to be irradiated for pain control.
•6. ECOG performance status 0-1.
•7. Life expectancy of at least 3 months.
•8. Resolution of all acute toxic effects (excluding alopecia) of any prior surgery, radiotherapy, radio-surgery or chemotherapy to NCI CTC (Version 3.0) Grade = 1 (exception: stable, grade 2 neuropathy is permitted).
•9. Baseline laboratory values fulfilling the following requirements:
•Absolute Neutrophils Count (ANC) = 1,500/mm3 (= 1.5 x 1000000000/L)
•Platelets= 75,000/mm3 (= 75 x 1000000000/L)
•Hemoglobin = 8.0 g/dL
•Serum Creatinine = 2.0 mg/dL ( = 177 micromol/L)
•Direct Serum Bilirubin = 1.5 x ULN
•Liver Transaminases (AST/ALT) = 2.5 x ULN; = 5 x ULN if liver involvement is present.
•10. Signed and dated informed consent indicating that the patient is aware of the neoplastic nature of his/her disease and has been informed of the procedures to be followed, the experimental nature of the therapy, potential benefits, side effects, discomforts, risks, and alternative treatments.
•11. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study indications or procedures.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Patients with non-detectable M-component (non-secretory myeloma).
•2. Current enrollment in another therapeutic clinical trial.
•3. Use of other investigational drugs (drugs not marketed for any indication) within 30 days prior to treatment.
•4. Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or superficial bladder cancer, ductal carcinoma in situ of the breast, or any other cancer from which the patient has been disease-free for 5 years or greater or that poses no immediate clinical threat to the patient.
•5. Prior treatment with radiopharmaceuticals (e.g., Strontium-89, Samarium-153) within 8 weeks prior to enrollment.
•6. Major surgery, within 4 weeks or not fully recovered prior to Day 1.
•7. Pregnancy or breast feeding. Male and female patients sexually active not using an effective form of barrier contraception during the study and in the following 90 days after discontinuation of study treatment.
•8. Uncontrolled hypertension with blood pressure exceeding 160/100 mmHg (Stage 2 hypertension according to the JNC 7/ NIH USA 2003 guideline).
•9. Any of the following in the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis.
•10. Cardiac dysrhythmias Grade = 2 according to NCI CTCAE version 3.0.
•11. Known active infections, including HIV positive.
•12. History of allergic reactions to a similar structural compound, biological agent, or formulation.
•13. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.

研究者

发起方

erviano Medical Sciences S.r.l.

相似试验

进行中（未招募）

不适用

A pilot Phase II study of PHA-739358 in patients with Chronic Myeloid Leukemia relapsing on Gleevec or c-ABL therapy - NDTreatment of Chronic Myeloid LeukemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemia

EUCTR2006-006881-40-ITERVIANO MEDICAL SCIENCES16

进行中（未招募）

1 期

EUCTR2006-003772-35-FRerviano Medical Sciences S.r.l.232

进行中（未招募）

不适用

EUCTR2006-003772-35-NLerviano Medical Sciences s.r.l232

已完成

2 期

NL-OMON33846erviano Medical Sciences Srl, Italy28

进行中（未招募）

1 期

Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers. - not availableAdvanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung, non small cell lung and squamous non small cell lung cancers.MedDRA version: 13.1Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10059514Term: Small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10033610Term: Pancreatic carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2006-003772-35-GBerviano Medical Sciences S.r.l.224